Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two doses of CDP323 over 24 weeks with a rater-blind MRI follow-up over 12 weeks.

Trial Profile

Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two doses of CDP323 over 24 weeks with a rater-blind MRI follow-up over 12 weeks.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs CDP 323 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors UCB
  • Most Recent Events

    • 23 Jun 2012 Primary endpoint (Drug concentration) added as reported by European Clinical Trials Database record.
    • 23 Jun 2012 Inclusion and exclusion criteria amended as reported by European Clinical Trials Database record.
    • 23 Jun 2012 Official Title amended as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top